UNSPSC 51401516: Clonazepam

This classification denotes a benzodiazepine and anticonvulsant agent with the molecular formula C15H10ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5PE9FDE8GB, chemically known as 1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2h-1,4.benzodiazepin-2-one but generally known as clonazepam, which bears US NIH Compound Identifier 2802. European Medicines Agency schedules Clonazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06728MIG.

UNSPSC 51401516 Clonazepam, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The single available recent opportunity—Seminole County, Florida's IFB60459723LAS—does not involve clonazepam procurement; instead, the county is sourcing naloxone and safe drug deactivation systems for community health initiatives. This mismatch suggests the code may be misapplied in state and local procurement databases or that clonazepam itself generates little direct solicitation activity at the county and municipal level. When state and local agencies do pursue pharmaceutical procurements under related codes, the work typically centers on emergency-response medications, harm-reduction supplies, and public-health consumables delivered on fixed schedules with standardized compliance requirements.

Seminole County's IFB, posted June 30, 2026 with a response deadline of July 26, 2023, required 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors were obligated to include all shipping and delivery costs in their bids, maintain workers' compensation and commercial general liability insurance, comply with drug-free workplace and E-Verify requirements, and potentially adhere to federal compliance standards if FEMA funding applied. The contract offered a two-year initial term with a one-year renewal option and included a three-month probationary termination clause. Beyond this single opportunity, the source provides no additional recent solicitations under the clonazepam code across other jurisdictions or states, indicating low current procurement volume or poor code alignment in state and local systems.